Cargando…
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991905/ https://www.ncbi.nlm.nih.gov/pubmed/36635391 http://dx.doi.org/10.1038/s41375-023-01809-z |
| _version_ | 1784902250323247104 |
|---|---|
| author | Zander, Thilo Pabst, Thomas Schär, Sämi Aebi, Stefan Mey, Ulrich Novak, Urban Lerch, Erika Rhyner Agocs, Gaëlle Goede, Jeroen Maniecka, Zuzanna Hayoz, Stefanie Rüfer, Axel Renner, Christoph Driessen, Christoph |
| author_facet | Zander, Thilo Pabst, Thomas Schär, Sämi Aebi, Stefan Mey, Ulrich Novak, Urban Lerch, Erika Rhyner Agocs, Gaëlle Goede, Jeroen Maniecka, Zuzanna Hayoz, Stefanie Rüfer, Axel Renner, Christoph Driessen, Christoph |
| author_sort | Zander, Thilo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9991905 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99919052023-03-09 Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial Zander, Thilo Pabst, Thomas Schär, Sämi Aebi, Stefan Mey, Ulrich Novak, Urban Lerch, Erika Rhyner Agocs, Gaëlle Goede, Jeroen Maniecka, Zuzanna Hayoz, Stefanie Rüfer, Axel Renner, Christoph Driessen, Christoph Leukemia Letter Nature Publishing Group UK 2023-01-12 2023 /pmc/articles/PMC9991905/ /pubmed/36635391 http://dx.doi.org/10.1038/s41375-023-01809-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Zander, Thilo Pabst, Thomas Schär, Sämi Aebi, Stefan Mey, Ulrich Novak, Urban Lerch, Erika Rhyner Agocs, Gaëlle Goede, Jeroen Maniecka, Zuzanna Hayoz, Stefanie Rüfer, Axel Renner, Christoph Driessen, Christoph Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title_full | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title_fullStr | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title_full_unstemmed | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title_short | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| title_sort | alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991905/ https://www.ncbi.nlm.nih.gov/pubmed/36635391 http://dx.doi.org/10.1038/s41375-023-01809-z |
| work_keys_str_mv | AT zanderthilo alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT pabstthomas alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT scharsami alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT aebistefan alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT meyulrich alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT novakurban alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT lercherika alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT rhyneragocsgaelle alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT goedejeroen alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT manieckazuzanna alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT hayozstefanie alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT ruferaxel alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT rennerchristoph alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial AT driessenchristoph alternatedaydosingofpomalidomideinrelapsedrefractorymultiplemyelomaamulticentersinglearmphase2trial |